Comparison between elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus

Clinical and Vaccine Immunology

Volumn 19, Issue 2, 2012, Pages 242-248

  Maylin, Sarah ^a,b,c   Boyd, Anders ^b   Delaugerre, Constance ^a,b,c   Zoulim, Fabien ^d,e,f   Lavocat, Fabien ^d   Simon, François ^a,b,c   Girard, Pierre Marie ^b,g,h   Lacombe, Karine ^b,g,h  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f UNIVERSITÉ LYON 1   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ACCURACY; ADULT; AMINO ACID SUBSTITUTION; ANTIGEN DETECTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY; CHEMOLUMINESCENCE; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DILUTION; ENVELOPE GENE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; PROTEIN MOTIF; QUANTITATIVE ASSAY; VIRUS LOAD; VIRUS MUTATION;

ADENINE; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REAGENT KITS, DIAGNOSTIC;

EID: 84856459853     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05454-11     Document Type: Article

References (33)

1. Bonino et al. 2011. Multicenter evaluation of the Elecsys HBsAg II Quant assay. Hepatol. Int. 5:80.
2. Borgniet O, et al. 2009. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. J. Med. Virol. 81:1336-1342.
3. Boyd A, et al. 2010. HBs antigen quantification as a marker of HBs and HBe antigens loss in HIV/HBV co-infected patients treated with tenofovir, p. 303, Abstr. 635. In 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010. San Francisco, CA.
4. Brunetto MR, et al. 2009. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatol. 49:1141-1150.
5. Cooreman MP, et al. 1999. Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring "a" loop escape mutations. Hepatology 30:1287-1292. (Pubitemid 29510868)
6. Deguchi M, et al. 2004. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J. Virol. Methods 115:217-222. (Pubitemid 37506037)
7. European Association for the Study of the Liver. 2009. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 50:227-242.
8. Heathcote EJ, et al. 2011. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140:132-143.
9. Lacombe K, et al. 2006. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 20:419-427.
10. Lee MH, Lee da M, Kim SS, Cheong JY, Cho SW. 2011. Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B. J. Med. Virol. 83:1178-1186.
11. Lin LY, et al. 2010. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. J. Med. Virol. 82:1494-1500.
12. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. 2007. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir. Ther. 12:73-82. (Pubitemid 46340428)
13. Moucari R, et al. 2009. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J. Hepatol. 50:1084-1092.
14. Moucari R, et al. 2009. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49:1151-1157.
15. NguyenT, et al. 2010. HepatitisBsurface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J. Hepatol. 52:508-513.
16. Reijnders JG, et al. 2011. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J. Hepatol. 54:449-454.
17. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. 2010. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 52:1251-1257.
18. Sonneveld MJ, et al. 2011. A comparison of two assays for quantification of hepatitis B surface antigen in patients with chronic hepatitis B. J. Clin. Virol. 51:175-178.
19. Thibault V, et al. 2011. Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. Antivir. Ther. 16:199-205.
20. Thompson AJ, et al. 2010. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51:1933-1944.
21. Tian Y, et al. 2007. The amino acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. J. Clin. Microbiol. 45:2971-2978. (Pubitemid 47417342)
22. Torresi J, et al. 2002. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers"subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 299:88-99. (Pubitemid 35007514)
23. Torresi J, et al. 2002. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293:305-313.
24. Tran N, et al. 2006. European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J. Clin. Microbiol. 44:2792-2800. (Pubitemid 44228573)
25. Vernet G, Tran N. 2005. The DNA-Chip technology as a new molecular tool for the detection of HBV mutants. J. Clin. Virol. 34(Suppl. 1):S49-S53. (Pubitemid 43197748)
26. Werle-Lapostolle B, et al. 2004. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126:1750 -1758.
27. Wiegand J, et al. 2008. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir. Ther. 13:547-554. (Pubitemid 352016717)
28. Wong GL, Chan HL. 2009. Predictors of treatment response in chronic hepatitis B. Drugs 69:2167-2177.
29. Wursthorn K, et al. 2011. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J. Clin. Virol. 50:292-296.
30. Wursthorn K, et al. 2010. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 52:1611-1620.
31. Zabelin NN, et al. 2010. Impact of changes in the amino acid sequence of the "a" determinant on the diagnostic capacities of test systems for the detection of HBsAg. Vopr. Virusol. 55:28 -31. (In Russian.)
32. Zacher BJ, et al. 2011. Multicenter evaluation of the Elecsys HBsAg II quant assay. Clin. Vaccine Immunol. doi:10.1128/CVI.05122-11.
33. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. 2011. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J. Infect. Dis. 204:415- 418.